679 related articles for article (PubMed ID: 35325852)
1. Gut microbiota-derived metabolites as key actors in type 2 diabetes mellitus.
Du L; Li Q; Yi H; Kuang T; Tang Y; Fan G
Biomed Pharmacother; 2022 May; 149():112839. PubMed ID: 35325852
[TBL] [Abstract][Full Text] [Related]
2. Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus.
Wu J; Yang K; Fan H; Wei M; Xiong Q
Front Endocrinol (Lausanne); 2023; 14():1114424. PubMed ID: 37229456
[TBL] [Abstract][Full Text] [Related]
3. Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus.
Zhou Z; Sun B; Yu D; Zhu C
Front Cell Infect Microbiol; 2022; 12():834485. PubMed ID: 35242721
[TBL] [Abstract][Full Text] [Related]
4. Gut Microbiota and Type 2 Diabetes Mellitus: Association, Mechanism, and Translational Applications.
Zhang L; Chu J; Hao W; Zhang J; Li H; Yang C; Yang J; Chen X; Wang H
Mediators Inflamm; 2021; 2021():5110276. PubMed ID: 34447287
[TBL] [Abstract][Full Text] [Related]
5. Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes.
Huda MN; Kim M; Bennett BJ
Front Endocrinol (Lausanne); 2021; 12():632335. PubMed ID: 33897618
[TBL] [Abstract][Full Text] [Related]
6. From role of gut microbiota to microbial-based therapies in type 2-diabetes.
Ebrahimzadeh Leylabadlo H; Sanaie S; Sadeghpour Heravi F; Ahmadian Z; Ghotaslou R
Infect Genet Evol; 2020 Jul; 81():104268. PubMed ID: 32126303
[TBL] [Abstract][Full Text] [Related]
7. The Gut Microbial Endocrine Organ in Type 2 Diabetes.
Massey W; Brown JM
Endocrinology; 2021 Feb; 162(2):. PubMed ID: 33373432
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota as the critical correlation of polycystic ovary syndrome and type 2 diabetes mellitus.
Duan L; An X; Zhang Y; Jin D; Zhao S; Zhou R; Duan Y; Zhang Y; Liu X; Lian F
Biomed Pharmacother; 2021 Oct; 142():112094. PubMed ID: 34449321
[TBL] [Abstract][Full Text] [Related]
9. Microbiomes in physiology: insights into 21st-century global medical challenges.
Shehata E; Parker A; Suzuki T; Swann JR; Suez J; Kroon PA; Day-Walsh P
Exp Physiol; 2022 Apr; 107(4):257-264. PubMed ID: 35081663
[TBL] [Abstract][Full Text] [Related]
10. Gut-targeted therapies for type 2 diabetes mellitus: A review.
Xu TC; Liu Y; Yu Z; Xu B
World J Clin Cases; 2024 Jan; 12(1):1-8. PubMed ID: 38292634
[TBL] [Abstract][Full Text] [Related]
11. Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review.
Li HY; Zhou DD; Gan RY; Huang SY; Zhao CN; Shang A; Xu XY; Li HB
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579087
[TBL] [Abstract][Full Text] [Related]
12. Role of Gut Microbiota on Onset and Progression of Microvascular Complications of Type 2 Diabetes (T2DM).
Tanase DM; Gosav EM; Neculae E; Costea CF; Ciocoiu M; Hurjui LL; Tarniceriu CC; Maranduca MA; Lacatusu CM; Floria M; Serban IL
Nutrients; 2020 Dec; 12(12):. PubMed ID: 33276482
[TBL] [Abstract][Full Text] [Related]
13. Metabolites Linking the Gut Microbiome with Risk for Type 2 Diabetes.
Zhu T; Goodarzi MO
Curr Nutr Rep; 2020 Jun; 9(2):83-93. PubMed ID: 32157661
[TBL] [Abstract][Full Text] [Related]
14. Gut Microbiome and Its Impact on Obesity and Obesity-Related Disorders.
Sankararaman S; Noriega K; Velayuthan S; Sferra T; Martindale R
Curr Gastroenterol Rep; 2023 Feb; 25(2):31-44. PubMed ID: 36469257
[TBL] [Abstract][Full Text] [Related]
15. Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites.
Wang D; Liu J; Zhou L; Zhang Q; Li M; Xiao X
Front Endocrinol (Lausanne); 2022; 13():905171. PubMed ID: 35909556
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic methods of gut microbiota modification in colorectal cancer management - fecal microbiota transplantation, prebiotics, probiotics, and synbiotics.
Kaźmierczak-Siedlecka K; Daca A; Fic M; van de Wetering T; Folwarski M; Makarewicz W
Gut Microbes; 2020 Nov; 11(6):1518-1530. PubMed ID: 32453670
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Dyslipidemia through Targeted Therapy of Gut Microbiota.
Flaig B; Garza R; Singh B; Hamamah S; Covasa M
Nutrients; 2023 Jan; 15(1):. PubMed ID: 36615885
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiota: A new target for T2DM prevention and treatment.
Liu L; Zhang J; Cheng Y; Zhu M; Xiao Z; Ruan G; Wei Y
Front Endocrinol (Lausanne); 2022; 13():958218. PubMed ID: 36034447
[TBL] [Abstract][Full Text] [Related]
19. Beneficial Effects of Essential Oils from the Mediterranean Diet on Gut Microbiota and Their Metabolites in Ischemic Heart Disease and Type-2 Diabetes Mellitus.
Sánchez-Quintero MJ; Delgado J; Medina-Vera D; Becerra-Muñoz VM; Queipo-Ortuño MI; Estévez M; Plaza-Andrades I; Rodríguez-Capitán J; Sánchez PL; Crespo-Leiro MG; Jiménez-Navarro MF; Pavón-Morón FJ
Nutrients; 2022 Nov; 14(21):. PubMed ID: 36364913
[TBL] [Abstract][Full Text] [Related]
20. Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
Okubo H; Nakatsu Y; Kushiyama A; Yamamotoya T; Matsunaga Y; Inoue MK; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Ono H; Asano T
Curr Med Chem; 2018; 25(9):984-1001. PubMed ID: 28990516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
